|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF91 |
Gene summary for ZNF91 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF91 | Gene ID | 7644 |
| Gene name | zinc finger protein 91 | |
| Gene Alias | HPF7 | |
| Cytomap | 19p12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q05481 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7644 | ZNF91 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.24e-35 | -7.84e-01 | 0.0155 |
| 7644 | ZNF91 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.69e-06 | -4.73e-01 | -0.1808 |
| 7644 | ZNF91 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.62e-04 | -7.59e-01 | 0.0216 |
| 7644 | ZNF91 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.36e-06 | -2.93e-01 | -0.0811 |
| 7644 | ZNF91 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.80e-03 | -3.44e-01 | -0.1088 |
| 7644 | ZNF91 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.30e-05 | -4.55e-01 | -0.1207 |
| 7644 | ZNF91 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.29e-03 | -4.68e-01 | -0.1526 |
| 7644 | ZNF91 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.24e-04 | -3.37e-01 | -0.1464 |
| 7644 | ZNF91 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.36e-07 | -3.58e-01 | -0.1001 |
| 7644 | ZNF91 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.32e-09 | -4.42e-01 | -0.059 |
| 7644 | ZNF91 | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.63e-06 | -4.93e-01 | -0.2061 |
| 7644 | ZNF91 | HTA11_5216_2000001011 | Human | Colorectum | SER | 4.01e-02 | -5.56e-01 | -0.1462 |
| 7644 | ZNF91 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.85e-02 | -4.69e-01 | -0.0842 |
| 7644 | ZNF91 | HTA11_7862_2000001011 | Human | Colorectum | AD | 6.01e-03 | -4.96e-01 | -0.0179 |
| 7644 | ZNF91 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.83e-34 | -8.34e-01 | 0.096 |
| 7644 | ZNF91 | HTA11_4255_2000001011 | Human | Colorectum | SER | 5.01e-03 | -7.06e-01 | 0.0446 |
| 7644 | ZNF91 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.91e-07 | -1.05e+00 | 0.0451 |
| 7644 | ZNF91 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.51e-05 | -6.73e-01 | 0.0528 |
| 7644 | ZNF91 | HTA11_10623_2000001011 | Human | Colorectum | AD | 9.13e-05 | -4.16e-01 | -0.0177 |
| 7644 | ZNF91 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.56e-07 | -4.77e-01 | 0.0338 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:00510521 | Colorectum | SER | regulation of DNA metabolic process | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
| GO:00510522 | Colorectum | MSS | regulation of DNA metabolic process | 108/3467 | 359/18723 | 5.86e-08 | 3.10e-06 | 108 |
| GO:00510524 | Colorectum | FAP | regulation of DNA metabolic process | 84/2622 | 359/18723 | 9.80e-07 | 4.38e-05 | 84 |
| GO:00510525 | Colorectum | CRC | regulation of DNA metabolic process | 70/2078 | 359/18723 | 1.75e-06 | 8.92e-05 | 70 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:0051053 | Liver | NAFLD | negative regulation of DNA metabolic process | 26/1882 | 125/18723 | 2.52e-04 | 4.12e-03 | 26 |
| GO:00510526 | Liver | NAFLD | regulation of DNA metabolic process | 56/1882 | 359/18723 | 5.95e-04 | 7.92e-03 | 56 |
| GO:005105211 | Liver | Cirrhotic | regulation of DNA metabolic process | 114/4634 | 359/18723 | 1.48e-03 | 9.85e-03 | 114 |
| GO:005105221 | Liver | HCC | regulation of DNA metabolic process | 198/7958 | 359/18723 | 7.62e-07 | 1.17e-05 | 198 |
| GO:00510529 | Prostate | BPH | regulation of DNA metabolic process | 89/3107 | 359/18723 | 4.07e-05 | 4.36e-04 | 89 |
| GO:005105212 | Prostate | Tumor | regulation of DNA metabolic process | 88/3246 | 359/18723 | 3.23e-04 | 2.59e-03 | 88 |
| GO:005105218 | Thyroid | PTC | regulation of DNA metabolic process | 171/5968 | 359/18723 | 2.52e-10 | 8.33e-09 | 171 |
| GO:00510532 | Thyroid | PTC | negative regulation of DNA metabolic process | 53/5968 | 125/18723 | 8.39e-03 | 3.53e-02 | 53 |
| GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
| GO:00510531 | Thyroid | ATC | negative regulation of DNA metabolic process | 57/6293 | 125/18723 | 3.47e-03 | 1.55e-02 | 57 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF91 | MLUM | Breast | IDC | N4BP2L2,XIST,SSFA2, etc. | 5.44e-01 |  |
| ZNF91 | CD8TCM | Cervix | N_HPV | ZNF708,ATM,MTHFR, etc. | 1.10e-01 |  |
| ZNF91 | M1MAC | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 1.24e-04 |  |
| ZNF91 | TFH | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 1.37e-05 | |
| ZNF91 | NEUT | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 2.62e-03 | |
| ZNF91 | MALTB | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 1.75e-04 | |
| ZNF91 | BMEM | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 8.21e-06 | |
| ZNF91 | GC | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 2.37e-04 | |
| ZNF91 | MDSC | Lung | ADJ | AC244131.2,SCGB3A2,SLC12A2, etc. | 0.00e+00 | |
| ZNF91 | CD4TN | Oral cavity | EOLP | CD200R1,JHY,PAXIP1-AS2, etc. | 1.44e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF91 | SNV | Missense_Mutation | c.2684N>T | p.Ser895Leu | p.S895L | Q05481 | protein_coding | deleterious(0) | possibly_damaging(0.807) | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| ZNF91 | SNV | Missense_Mutation | c.635G>C | p.Cys212Ser | p.C212S | Q05481 | protein_coding | deleterious(0.01) | possibly_damaging(0.597) | TCGA-A2-A0YG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| ZNF91 | SNV | Missense_Mutation | c.920N>T | p.Ser307Leu | p.S307L | Q05481 | protein_coding | deleterious(0.01) | benign(0.199) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF91 | SNV | Missense_Mutation | c.1025N>A | p.Arg342Lys | p.R342K | Q05481 | protein_coding | tolerated(0.35) | benign(0.086) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF91 | SNV | Missense_Mutation | novel | c.1676N>T | p.Ser559Leu | p.S559L | Q05481 | protein_coding | deleterious(0) | benign(0.078) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF91 | SNV | Missense_Mutation | c.2905N>A | p.Glu969Lys | p.E969K | Q05481 | protein_coding | tolerated(0.72) | possibly_damaging(0.863) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ZNF91 | SNV | Missense_Mutation | c.3305G>C | p.Gly1102Ala | p.G1102A | Q05481 | protein_coding | deleterious(0.04) | probably_damaging(0.928) | TCGA-E2-A14X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| ZNF91 | SNV | Missense_Mutation | novel | c.2635G>C | p.Glu879Gln | p.E879Q | Q05481 | protein_coding | deleterious(0.02) | probably_damaging(0.964) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| ZNF91 | SNV | Missense_Mutation | c.2301G>C | p.Glu767Asp | p.E767D | Q05481 | protein_coding | deleterious(0.05) | possibly_damaging(0.598) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| ZNF91 | SNV | Missense_Mutation | novel | c.1961G>C | p.Gly654Ala | p.G654A | Q05481 | protein_coding | deleterious(0.01) | possibly_damaging(0.671) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |